Patients’ rationale for declining participation in a cancer-associated weight loss study
Tóm tắt
Fewer than 5 % of cancer patients participate in clinical research. Although this paltry rate has led to extensive research on this topic, previous studies have not sought verbatim comments in a real-time, comprehensive manner to understand why patients decline. This study used a low-risk, non-interventional parent study that focused on cancer-associated weight loss to understand patients’ reasons for declining research participation. A research assistant wrote down the name and verbatim reason of all patients who declined to participate. These comments with accompanying patient demographic data are the subject of this report. Of the 334 patients, 51 (15 %) declined parent study enrollment; three comment-related themes emerged: (1) a repelling sense of too much institutional research, (2) overwhelming personal health issues, and (3) a low likelihood of returning to the institution. In univariate and multivariate analyses, only age (older) and gender (female) were associated with non-enrollment. Interestingly, 41 patients with fatigue scores of 7 or worse and 26 with pain scores of 7 or worse were enrolled. Although many factors were associated with declining to participate in research, symptom severity was not. Upfront education might help cancer patients better prioritize their participation in research, particularly as some patients felt overwhelmed by too much research in the institution; and for now, investigators should continue to keep asking patients for their participation.
Tài liệu tham khảo
Klabunde CN, Keating NL, Potosky AL, et al. A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst February 22, 2011
Jenkins V, Farewell V, Farewell D, et al. Drivers and barriers to patient participation in RCTs. Br J Cancer. 2013;108:1402–7.
Fouad MN, Lee JY, Catalano PJ, et al. Enrollment of patients with lung and colorectal cancers onto clinical trials. J Oncol Pract. 2013;9:e40–7.
Horn L, Keedy VL, Campbell N, et al. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin Lung Cancer. 2013;14:14–8.
Bierrzycki BA. Factors and outcomes of decision making for cancer clinical trial participation. Oncol Nurs Forum. 2011;38:542–52.
Yang ZJ, McCopmas KA, Gay GK, et al. Comparing decision making between cancer patients and the general population: thoughts, emotions, and social influence? J Health Commun. 2012;17:477–94.
Javid SH, Unger JM, Gralow JR, et al. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials. Oncologist. 2012;17:1180–90.
Ford M, Wahlquist A, Blake R, et al. Assessing an intervention to improve clinical trial perceptions among predominantly African-American communities in South Carolina. Prog Commun Health Partnership. 2012;6:249–63.
Penberthy L, Brown R, Wilson-Genderson M, et al. Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment. Clin Trials. 2012;9:788–97.
Gerber DE, Rasco DW, Skinner CS, et al. Consent timing and experience: modifiable factors that may influence interest in clinical research. JOP. 2012;8:91–6.
Mazanec S, Daly B, Meropol NJ, Step M. Facilitating enrollment in a cancer registry through modified consent procedures. J Empir Res Hum Res Ethics. 2012;7:71–5.
Jacobs SR, Weiner BJ, Minasian LM, Good MJ. Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program. Contemp Clin Trials. 2013;34:320–5.
Barnhill RL, Piepkorn MW, Cochran AJ, Flynn E, Karaoli T, Folkman J. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch Dematol. 1998;134:991–4.
Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815–21.
Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol. 2007;17:643–53.
Chow CJ, Habemann EB, Abraham A, et al. Does enrollment in cancer trials improve survival? J An Coll Surg. 2013;21:774–80.
Schwentner L, Van Ewijk R, Kurzeder C, et al. Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients. Eur J Cancer. 2013;49:553–63.
Sloan JA, Aaronson N, Cappelleri JC, et al. Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc. 2002;77:479–87.
Pope C, Zieband S, Mays N. Qualitative research in health care. Analysing qualitative data. BMJ. 2000;320:114–6.
Green J, Britten N. Qualitative research and evidence based medicine. BMJ. 1998;316:1230–2.
Greenhalgh T, Taylor R. Papers that go beyond numbers (qualitative research). BMJ. 1997;315:740–3.
Unger JM, Hershman DL, Albain KS, et al. Patient income level and cancer clinical trial participation. J Clin Oncol. 2013;31:536–42.
Jenkins V, Farewell D, Batt L, et al. The attitudes of 1066 patients with cancer towards participation in randomized clinical trials. Br J Cancer. 2010;103:1801–7.